BioMedNewsBreaks

WednesdayMay 07, 2025 12:28 pm

BioMedNewsBreaks — Soligenix Inc. (SNGX) CEO Highlights Pipeline and Strategy in Latest BioMedWire Podcast Episode

Soligenix (SNGX) Chairman and CEO Dr. Christopher Schaber joined IBN’s BioMedWire Podcast to discuss the company’s two-pronged business model, robust late-stage pipeline, and ongoing clinical trials. Schaber emphasized Soligenix’s focus on rare disease therapeutics and its Public Health Solutions segment, which has received over $60 million in non-dilutive U.S. government funding. He also outlined near-term milestones, including a confirmatory Phase 3 trial, active partnership discussions, and continued pursuit of strategic opportunities.  To view the full press release, visit https://ibn.fm/cdTsU  About Soligenix, Inc.  Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there…

Continue Reading

TuesdayMay 06, 2025 11:44 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio 

HeartBeam (NASDAQ: BEAT), a medical technology company advancing personalized cardiac care, announced the issuance of two new U.S. patents that strengthen its intellectual property position. The first patent covers the company’s credit card-sized, cable-free 3D ECG device, which enables real-time cardiac monitoring and symptom capture. The second patent protects its rhythm analysis algorithm, which identifies arrhythmias using continuous signal input and prompts users to collect 3D ECG data when anomalies are detected. These additions expand HeartBeam’s patent count to 20 issued and 34 others pending or allowed, reinforcing its platform ahead of future product extensions and FDA review of its…

Continue Reading

TuesdayMay 06, 2025 10:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) to Announce Q1 2025 Results on May 15, Hosts Investor Call at 8:30 a.m.

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, will release its financial results for the quarter ended March 31, 2025, before market open on May 15. Management will host a conference call at 8:30 a.m. EDT the same day, led by Executive Chairman and CEO Charles M. Fernandez, CFO Cecile Munnik, and President and CEO of Global Operations David Phipps. To view the full press release, visit: https://ibn.fm/ttpQg About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends…

Continue Reading

MondayMay 05, 2025 9:30 am

BioMedNewsBreaks — VERAXA Biotech AG Launches Bispecific ADC Discovery Alliance with OmniAb (NASDAQ: OABI) 

VERAXA Biotech AG, a cancer therapy innovator, and proposed de-SPAC target of Voyager Acquisition Corp. (NASDAQ: VACH), announced a co-discovery alliance with OmniAb Inc. (NASDAQ: OABI) to jointly develop a novel bispecific antibody drug conjugate (“bsADC”) program targeting solid tumors. The collaboration combines OmniAb’s transgenic antibody discovery platform with VERAXA’s proprietary ADC linker and conjugation technology to create next-generation cancer therapeutics. Under the agreement, VERAXA will lead preclinical development using two selected cancer targets, while both companies will co-own the program and share future revenues from its advancement, licensing and commercialization. This marks VERAXA’s second major strategic initiative in six…

Continue Reading

MondayMay 05, 2025 9:24 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints CEO Robert Eno to Board of Directors 

HeartBeam (NASDAQ: BEAT) a medical technology company advancing personalized cardiac care, has appointed Chief Executive Officer Robert Eno to its Board of Directors, expanding the board from eight to nine members. Eno, who joined the company as president in January 2023 and became CEO in October 2024, brings over 30 years of medtech leadership experience, including launching disruptive technologies. His appointment comes as the company prepares for the commercial launch of its 3D ECG technology, pending FDA clearance of its 12-lead ECG synthesis software.  To view the full press release, visit https://ibn.fm/7SiVW  About HeartBeam Inc.  HeartBeam is a medical technology…

Continue Reading

ThursdayMay 01, 2025 2:07 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Launches Upgrade to Empower Patients, Drive Better Outcomes 

HealthLynked (OTCQB: HLYK) today announced a major enhancement to its appointment booking capabilities, further expanding patient access to care across its growing network of healthcare providers. “At HealthLynked, our mission is to connect patients with the best possible healthcare, faster and more efficiently,” said Dr. Michael Dent, CEO of HealthLynked. “These latest enhancements expand access to care — whether through in-network booking, concierge appointment requests, or specialty-based provider matching. Just as importantly, our new provider review system gives patients real feedback from other users, helping them make better, more confident decisions about their healthcare. Together, these improvements strengthen the patient…

Continue Reading

ThursdayMay 01, 2025 11:27 am

BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation.  To view the full press release, visit https://ibn.fm/ZYCaL  About TransCode Therapeutics  TransCode is a clinical-stage oncology company…

Continue Reading

ThursdayMay 01, 2025 10:25 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a $4.3 million New Drug Application filing fee waiver from the FDA for NRX-100, its preservative-free ketamine therapy for suicidal depression. The waiver, granted to small businesses and drugs deemed essential for public health, enables NRx to complete its NDA by the end of Q2 2025 using existing resources. NRX-100 offers a single-patient ketamine formulation without benzethonium chloride, a preservative associated with neurotoxicity. The company aims to secure FDA approval to provide insurance-covered treatment options beyond current off-label use.  To view the full press release, visit https://ibn.fm/C6SGv  About NRx Pharmaceuticals, Inc.  NRx…

Continue Reading

ThursdayMay 01, 2025 10:08 am

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders 

Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program. Panelists include executives from Scinai and Pincell, with a live Q&A segment.  To view the full press release, visit https://ibn.fm/BunpC  About Scinai Immunotherapeutics Ltd.  Scinai is a biopharmaceutical company with two…

Continue Reading

ThursdayMay 01, 2025 9:40 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13

HeartBeam (NASDAQ: BEAT) will host a conference call on May 13 at 4:30 p.m. Eastern to discuss financial results for the first quarter ended March 31, 2025. CEO Robert Eno and CFO Timothy Cruickshank will lead the call, which will include updates on regulatory progress, commercial-readiness efforts, and upcoming milestones. A corresponding press release and presentation will be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/HOwza About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the…

Continue Reading